Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered
Keywords: Alzheimer's disease (AD); Arylpropionic Acids; Benzenesulfonanilide; COX-1 inhibition; Creutzfeldt-Jacob disease; Curcumin; Cyclooxygenase; Diarylheterocycles; Dipyrone; Nephrotoxic syndromes; Neuropathic pain; Oxicams; Parkinson's disease (PD); Pyrazolones; Salicylic acid; Stilbenes; Sulindac Derivatives; acetaminophen; adenocarcinoma; arachidonic acid; aspirin; atherosclerotic plaque; atherothrombosis; blood-brain barrier (BBB); celecoxib; cyclooxygenase; cyclooxygenase (COX); enzyme immunoassay; epileptogenesis; hippocampus; homeostasis; housekeeping gene; hydroperoxide; indomethacin; interleukin; isozymes; leptomeninges; lipopolysaccha-ride; lipopolysaccharide; microglia; mofezolac; mutagenesis; neoplasias; neuro-inflammation; neurodegenerative disorders; neuroinflammation; nociceptors; nonsteroidal anti-inflammatory drugs; phorbol myristate acetate; po-larographic oxygen electrode; prostacyclin; prostaglandin; prostanoids; radioimmunological assay; renal electrolyte; rofecoxib; selective inhibitors; structure-activity relationships; thromboxane; traumatic brain injury; tumor necrosis factor; tumorigenesis; tumorigenicity; ventrolateral medulla (VLM); ventromedial preoptic nucleus (VMPO)
Document Type: Research Article
Publication date: 01 November 2010
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.